Study to Describe Risk of Bleeding in Patients Depending on the Different Anticoagulant Therapy They Are on for Atrial Fibrillation (AF)

NCT03508258 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2022-06-30

No results posted yet for this study

Summary

Study of patients with nonvalvular atrial fibrillation (NVAF) who are newly prescribed NOACs (Novel Oral Anticoagulants) in routine clinical practice in England

Conditions

  • Non-valvular Atrial Fibrillation

Interventions

OTHER

Non-interventional

Non-interventional

OTHER

Non-Interventional

Non-Interventional

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-01
Primary Completion
2018-09-01
Completion
2018-09-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03508258 on ClinicalTrials.gov